The antipsychotic potential of muscarinic allosteric modulation
about
Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicologyDiscovery of ML326: The first sub-micromolar, selective M5 PAMTargeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Development of allosteric modulators of GPCRs for treatment of CNS disordersFrom revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's DiseaseAllosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discoveryNonoisotopic assay for the presynaptic choline transporter reveals capacity for allosteric modulation of choline uptake.Classics in chemical neuroscience: clozapine.Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: a review.Novel M(1) allosteric ligands: a patent review.Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012).Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetrationDiscovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe.Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.Synthesis and biological characterization of a series of novel diaryl amide M₁ antagonists.Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor.Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012.Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia.Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping.Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core.Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia.LY2033298, a positive allosteric modulator at muscarinic M₄ receptors, enhances inhibition by oxotremorine of light-induced phase shifts in hamster circadian activity rhythms.Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior.A novel M1 PAM VU0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity.
P2860
Q24627240-F9FBDA49-3DF5-413F-B250-40756740F9CDQ28288485-A0899426-7C7E-4C67-9F5E-03512214EBA4Q30446914-988BB619-8E52-47DC-B31C-396A7BDC92FCQ34169978-485BF915-67DA-4504-AF39-E2E9203D0566Q34373958-8B34FAC4-D082-4940-B899-B65EA33FBB7EQ34632695-00D15D99-9C9F-479B-8897-C7AA92BE54D4Q35048154-25BBFCBE-A652-4963-AA3B-0A66490C67C7Q35614156-F023286F-5B09-441E-ABDF-76358D992087Q35789730-1C54CF9A-CABF-49B8-B71F-8FC2E02425BFQ35952381-E1A48302-AD78-462F-9F35-05FFB1088C22Q36326822-14C61ABF-747D-4490-AE29-7E6714D81564Q37025878-75156AF3-2D3F-41D6-99A3-D3450773ED78Q37920918-07A15003-7BC2-4619-A7F5-0A497301AABDQ38054855-9870D0E0-CA9A-47B0-999D-E50502C5BD4BQ38162957-6457F333-AAE5-4133-8634-48E12D5ABAA5Q39077987-901DF23A-F190-47A0-9C0E-442FA5EC122BQ41594414-DDD98F88-D16C-4357-AEEA-0F5EA4902FD8Q41828999-17EC04AC-B118-4AF2-8B7A-D361E063B2ADQ41855867-0E92F8E7-BD24-4053-8705-99A4EFDA00ACQ41881891-19437B7F-6262-4859-82BD-99C40A8466B8Q42154556-50ADCF52-E85D-4C4B-B574-A707971CD600Q42323359-293E3887-D4B7-49DB-8DDD-EF9C29C20D60Q46417915-12E6977C-5443-4147-9950-987822AA385AQ47644788-5B3D7413-BE21-4A4B-BE90-608661F010ABQ47864774-90B50F0B-292D-400D-AB74-43A9EBCC854CQ48001582-7DF404A2-F901-465D-B807-B04BDEB51BB3Q48243771-B36F4DED-D247-4048-A251-F86D9016D625Q48354605-5667FEFF-129B-4B17-B662-D1334247E697Q52558952-A93F0847-F26A-4669-80DD-2382AD1E4B2B
P2860
The antipsychotic potential of muscarinic allosteric modulation
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The antipsychotic potential of muscarinic allosteric modulation
@ast
The antipsychotic potential of muscarinic allosteric modulation
@en
The antipsychotic potential of muscarinic allosteric modulation
@nl
type
label
The antipsychotic potential of muscarinic allosteric modulation
@ast
The antipsychotic potential of muscarinic allosteric modulation
@en
The antipsychotic potential of muscarinic allosteric modulation
@nl
prefLabel
The antipsychotic potential of muscarinic allosteric modulation
@ast
The antipsychotic potential of muscarinic allosteric modulation
@en
The antipsychotic potential of muscarinic allosteric modulation
@nl
P2093
P2860
P1476
The antipsychotic potential of muscarinic allosteric modulation
@en
P2093
Carrie K Jones
Corey R Hopkins
Evan P LeBois
Michael R Wood
Thomas M Bridges
P2860
P304
P356
10.1358/DNP.2010.23.4.1416977
P407
P577
2010-05-01T00:00:00Z